Clinical, Biochemical, and Molecular Characterization of Indian Children with Clinically Suspected Androgen Insensitivity Syndrome.

46,XY DSD Androgen receptor gene Complete androgen insensitivity syndrome Gynecomastia Orchidectomy Partial androgen insensitivity syndrome Pathogenic variants Undervirilization

Journal

Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation
ISSN: 1661-5433
Titre abrégé: Sex Dev
Pays: Switzerland
ID NLM: 101316472

Informations de publication

Date de publication:
2022
Historique:
received: 15 02 2021
accepted: 16 08 2021
pubmed: 25 10 2021
medline: 23 3 2022
entrez: 24 10 2021
Statut: ppublish

Résumé

This study describes the clinical, biochemical, and molecular characteristics of Indian children with 46,XY DSD and suspected androgen insensitivity syndrome (AIS). Fifty children (median age 3.0 years, range 0-16.5 years) with 46,XY DSD and a suspected diagnosis of AIS were enrolled. Sanger sequencing was performed to identify pathogenic variants in the androgen receptor (AR) gene and to study genotype-phenotype correlations. All 5 (100%) patients with CAIS and 14/45 (31%) patients with PAIS had pathogenic/likely pathogenic variants in the AR gene (overall, 14 different variants in 19 patients; 38.8%). There was no significant difference in clinical (cryptorchidism, hypospadias, or external masculinizing score) or biochemical parameters (gonadotropins and testosterone) between patients with or without pathogenic variants. However, patients with AIS were more likely to have a positive family history, be assigned female gender at birth, and present with gynaecomastia at puberty. Three novel pathogenic/likely pathogenic variants, including one splice donor site variant c.2318+1G>A, one frameshift variant p.H790Lfs*40, and one missense variant p.G821E, were identified in 3 patients with CAIS. The missense variant p.G821E was predicted as deleterious, damaging, disease-causing, and likely functionally inactive by in silico analysis and protein modelling study. Two previously not reported pathogenic/likely pathogenic variants, including p.R386H and p.G396R, were identified in patients with PAIS. This study contributes in expanding the spectrum of pathogenic variants in the AR gene in patients with AIS. Only 31% patients with a provisional diagnosis of PAIS had pathogenic variants in the AR gene, suggesting other possible mechanisms or candidate genes may be responsible for such a phenotypic presentation.

Identifiants

pubmed: 34689141
pii: 000519047
doi: 10.1159/000519047
doi:

Substances chimiques

Receptors, Androgen 0
Testosterone 3XMK78S47O

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-45

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Anil Kumar (A)

Division of Pediatric Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India, anilaiims9@gmail.com.

Rajni Sharma (R)

Division of Pediatric Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Mohammed Faruq (M)

Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.

Manoj Kumar (M)

Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.

Shilpa Sharma (S)

Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.

Ralf Werner (R)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany.
Institute of Molecular Medicine, University of Lübeck, Lübeck, Germany.

Olaf Hiort (O)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany.

Jain Vandana (J)

Division of Pediatric Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH